News
Cortex to Provide Shareholder Update and Host Conference Call on September 19, 2007
Irvine, CA (September 17, 2007) — Cortex Pharmaceuticals, Inc. (AMEX: COR) will host a conference call on Wednesday, September 19, 2007 at 4:00 PM EDT (1:00 PM PDT) to update shareholders on recent clinical, regulatory, and research activities related to their Ampakine® technology platform and to discuss relevant financial , patent, and business development activities at Cortex.
Participants are asked to call the following numbers 5-10 minutes prior to the starting time:
- From the U.S. and Canada: 1-866-585-6398
- International: 1-416-849-9626
A replay will be available for two weeks after the call by dialing 1-866-245-6755 (US and Canada) or 1-416-915-1035 (International) and entering access code 949915 when prompted.
For more information, call: Erika Moran or Tom Caden at The Investor Relations Group, Inc. Phone: 212-825-3210.
Cortex Pharmaceuticals, Inc.
Cortex, located in Irvine, California, is a neuroscience company focused on novel drug therapies for neurological and psychiatric disorders. Cortex is pioneering a class of proprietary pharmaceuticals called Ampakine compounds, which act to increase the strength of signals at connections between brain cells. The loss of these connections is thought to be responsible for memory and behavior problems in Alzheimer’s disease. Many psychiatric diseases, including schizophrenia, occur as a result of imbalances in the brain’s neurotransmitter system. These imbalances may be improved by using the Ampakine technology. Cortex has an alliance with N.V. Organon for the treatment of schizophrenia and depression. In December 2006 Cortex terminated the research collaboration with Servier enabling Cortex to pursue the use of Ampakine compounds in the treatment of neurodegenerative diseases on a global basis. Servier retained the right to select up to three compounds developed during the collaboration for further development for the treatment of neurodegenerative diseases. Cortex may receive additional milestones and royalties if either Organon or Servier is successful in developing and commercializing Ampakine compounds. For additional information regarding Cortex, please visit Cortex Pharmaceuticals’ Website at www.cortexpharm.com.
Forward-Looking Statement
Note - This press release contains forward-looking statements concerning the Company's research and development activities. The success of such activities depends on a number of factors, including the risks that the Company's proposed compounds may at any time be found to be unsafe or ineffective for the indications under clinical test and that clinical studies may at any point be suspended or take substantially longer than anticipated to complete. The forward-looking statements are necessarily subject to risks and uncertainties, all of which are difficult or impossible to predict accurately and many of which are beyond the control of Cortex, all as more fully described in the risk factors and other matters set forth in Cortex's Annual Report on Form 10-K for the year ended December 31, 2006, and Cortex's other filings with the Securities and Exchange Commission, As discussed in the Company's Securities and Exchange Commission filings, the Company's proposed products will require additional research, lengthy and costly clinical testing and regulatory approval. Ampakine compounds are investigational drugs and have not been approved for the treatment of any disease. Cortex disclaims any intent or obligation to update any forward-looking statements.
Contacts:
Roger G. Stoll, Ph.D.
Chairman, President and CEO
Cortex Pharmaceuticals, Inc.
(949) 727-3157
Erika Moran/Dian Griesel, Ph.D.
The Investor Relations Group
(212) 825-3210 |